aspirin has been researched along with Bile Duct Cancer in 21 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We aimed to examine aspirin use on cancer-specific survival in various BTC subtypes, including gallbladder cancer, ampulla of Vater cancer, and cholangiocarcinoma." | 8.02 | Postdiagnosis Aspirin Use Associated With Decreased Biliary Tract Cancer-Specific Mortality in a Large Nationwide Cohort. ( Chan, C; Chen, CJ; Chen, YJ; Hsieh, RJ; Huang, C; Huang, CP; Huang, YH; Jackson, SS; Koshiol, J; Lee, MH; Liao, SF; Liu, PC; Lu, SN; Shen, CY, 2021) |
| " Aspirin has many properties including anti-inflammation and anti-cancer." | 7.83 | Combination of Praziquantel and Aspirin Minimizes Liver Pathology of Hamster Opisthorchis viverrini Infection Associated Cholangiocarcinoma. ( Aukkanimart, R; Boonmars, T; Jiraporn, S; Loilome, W; Nadchanan, W; Namwat, N; Ruangjirachuporn, W; Sriraj, P; Sudsarn, P, 2016) |
| "Whether aspirin use is protective against cholangiocarcinoma (CCA) remains unclear." | 7.83 | Aspirin use and the risk of cholangiocarcinoma. ( Addissie, BD; Baichoo, E; Chaiteerakij, R; Choi, J; Ghoz, HM; Harmsen, WS; Olson, JE; Peeraphatdit, T; Roberts, LR; Therneau, TM, 2016) |
| "To investigate whether there is an inverse association between NSAIDs, including aspirin, and the development of cholangiocarcinoma and, for the first time in a Western population, between statin use and the development of cholangiocarcinoma." | 7.80 | Aspirin may prevent cholangiocarcinoma: a case-control study from the United kingdom. ( Burr, NE; Clark, A; Dennison, A; Hart, AR; Lewis, MP; Metcalfe, M; Phillips, M; Rhodes, M; Robinson, R; Rushbrook, S; Savva, S; Talboys, RJ, 2014) |
| "Cholangiocarcinoma is the second most common primary hepatic cancer, with a rising incidence worldwide." | 6.72 | A potential role for aspirin in the prevention and treatment of cholangiocarcinoma. ( Shen, X, 2021) |
| "Cholangiocarcinoma is the most common biliary duct malignancy and the second most common primary liver cancer, accounting for 10‑20% of hepatic malignancies." | 5.62 | Aspirin inhibits cholangiocarcinoma cell proliferation via cell cycle arrest in vitro and in vivo. ( Fujita, K; Gong, J; Iwama, H; Kobara, H; Liu, S; Masaki, T; Morishita, A; Nakahara, M; Nishiyama, N; Nonura, T; Okano, K; Shi, T; Suzuki, Y; Yoneyama, H, 2021) |
| " We aimed to examine aspirin use on cancer-specific survival in various BTC subtypes, including gallbladder cancer, ampulla of Vater cancer, and cholangiocarcinoma." | 4.02 | Postdiagnosis Aspirin Use Associated With Decreased Biliary Tract Cancer-Specific Mortality in a Large Nationwide Cohort. ( Chan, C; Chen, CJ; Chen, YJ; Hsieh, RJ; Huang, C; Huang, CP; Huang, YH; Jackson, SS; Koshiol, J; Lee, MH; Liao, SF; Liu, PC; Lu, SN; Shen, CY, 2021) |
| " Aspirin has many properties including anti-inflammation and anti-cancer." | 3.83 | Combination of Praziquantel and Aspirin Minimizes Liver Pathology of Hamster Opisthorchis viverrini Infection Associated Cholangiocarcinoma. ( Aukkanimart, R; Boonmars, T; Jiraporn, S; Loilome, W; Nadchanan, W; Namwat, N; Ruangjirachuporn, W; Sriraj, P; Sudsarn, P, 2016) |
| "Whether aspirin use is protective against cholangiocarcinoma (CCA) remains unclear." | 3.83 | Aspirin use and the risk of cholangiocarcinoma. ( Addissie, BD; Baichoo, E; Chaiteerakij, R; Choi, J; Ghoz, HM; Harmsen, WS; Olson, JE; Peeraphatdit, T; Roberts, LR; Therneau, TM, 2016) |
| "To investigate whether there is an inverse association between NSAIDs, including aspirin, and the development of cholangiocarcinoma and, for the first time in a Western population, between statin use and the development of cholangiocarcinoma." | 3.80 | Aspirin may prevent cholangiocarcinoma: a case-control study from the United kingdom. ( Burr, NE; Clark, A; Dennison, A; Hart, AR; Lewis, MP; Metcalfe, M; Phillips, M; Rhodes, M; Robinson, R; Rushbrook, S; Savva, S; Talboys, RJ, 2014) |
| "Cholangiocarcinoma is the second most common primary hepatic cancer, with a rising incidence worldwide." | 2.72 | A potential role for aspirin in the prevention and treatment of cholangiocarcinoma. ( Shen, X, 2021) |
| "Metformin was not associated with BTC risk (HR, 0." | 1.72 | Aspirin, Statins, Non-aspirin NSAIDs, Metformin, and the Risk of Biliary Cancer: A Swedish Population-Based Cohort Study. ( Borad, MJ; Brusselaers, N; Harmsen, WS; Marcano-Bonilla, L; Patel, T; Petersen, GM; Roberts, LR; Sadr-Azodi, O; Schleck, CD; Therneau, TM, 2022) |
| "Cholangiocarcinoma is the most common biliary duct malignancy and the second most common primary liver cancer, accounting for 10‑20% of hepatic malignancies." | 1.62 | Aspirin inhibits cholangiocarcinoma cell proliferation via cell cycle arrest in vitro and in vivo. ( Fujita, K; Gong, J; Iwama, H; Kobara, H; Liu, S; Masaki, T; Morishita, A; Nakahara, M; Nishiyama, N; Nonura, T; Okano, K; Shi, T; Suzuki, Y; Yoneyama, H, 2021) |
| "RECK functions as a metastasis suppressor in CCA; upregulation of RECK expression could provide a potential therapy to improve the prognosis of this type of cancer." | 1.37 | Downregulation of reversion-inducing-cysteine-rich protein with Kazal motifs (RECK) is associated with enhanced expression of matrix metalloproteinases and cholangiocarcinoma metastases. ( Khuntikeo, N; Loilome, W; Namwat, N; Puapairoj, A; Puetkasichonpasutha, J; Sripa, B; Tassaneeyakul, W; Techasen, A; Wongkham, S; Yongvanit, P, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 13 (61.90) | 24.3611 |
| 2020's | 8 (38.10) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, JH | 1 |
| Lee, KJ | 1 |
| Paik, WH | 1 |
| Park, N | 1 |
| Chun, JW | 1 |
| Lee, SH | 1 |
| Ryu, JK | 1 |
| Kim, YT | 1 |
| Marcano-Bonilla, L | 1 |
| Schleck, CD | 1 |
| Harmsen, WS | 2 |
| Sadr-Azodi, O | 2 |
| Borad, MJ | 1 |
| Patel, T | 1 |
| Petersen, GM | 1 |
| Therneau, TM | 2 |
| Roberts, LR | 2 |
| Brusselaers, N | 2 |
| Stefanini, B | 1 |
| Tonnini, M | 1 |
| Marseglia, M | 1 |
| Tovoli, F | 2 |
| Shen, X | 2 |
| Kim, MH | 1 |
| Park, SM | 1 |
| Chang, J | 1 |
| Hwang, IC | 1 |
| Shi, T | 1 |
| Gong, J | 1 |
| Fujita, K | 1 |
| Nishiyama, N | 1 |
| Iwama, H | 1 |
| Liu, S | 1 |
| Nakahara, M | 1 |
| Yoneyama, H | 1 |
| Morishita, A | 1 |
| Nonura, T | 1 |
| Kobara, H | 1 |
| Okano, K | 1 |
| Suzuki, Y | 1 |
| Masaki, T | 1 |
| Liao, SF | 1 |
| Koshiol, J | 1 |
| Huang, YH | 2 |
| Jackson, SS | 1 |
| Chan, C | 1 |
| Huang, C | 1 |
| Liu, PC | 1 |
| Chen, YJ | 1 |
| Hsieh, RJ | 1 |
| Huang, CP | 1 |
| Lu, SN | 1 |
| Chen, CJ | 1 |
| Shen, CY | 1 |
| Lee, MH | 1 |
| Kamal, H | 1 |
| Engstrand, L | 1 |
| Lapumnuaypol, K | 3 |
| Tiu, A | 3 |
| Thongprayoon, C | 3 |
| Wijarnpreecha, K | 3 |
| Ungprasert, P | 3 |
| Mao, MA | 3 |
| Cheungpasitporn, W | 3 |
| Lai, SW | 1 |
| Du, MH | 1 |
| Chu, KC | 1 |
| Cheng, SW | 1 |
| Bai, CH | 1 |
| Hsu, YP | 1 |
| Burr, NE | 1 |
| Talboys, RJ | 1 |
| Savva, S | 1 |
| Clark, A | 1 |
| Phillips, M | 1 |
| Metcalfe, M | 1 |
| Dennison, A | 1 |
| Robinson, R | 1 |
| Lewis, MP | 1 |
| Rhodes, M | 1 |
| Rushbrook, S | 1 |
| Hart, AR | 1 |
| Fujikawa, T | 1 |
| Tanaka, A | 1 |
| Sudsarn, P | 1 |
| Boonmars, T | 1 |
| Ruangjirachuporn, W | 1 |
| Namwat, N | 2 |
| Loilome, W | 2 |
| Sriraj, P | 1 |
| Aukkanimart, R | 1 |
| Nadchanan, W | 1 |
| Jiraporn, S | 1 |
| Choi, J | 1 |
| Ghoz, HM | 1 |
| Peeraphatdit, T | 1 |
| Baichoo, E | 1 |
| Addissie, BD | 1 |
| Olson, JE | 1 |
| Chaiteerakij, R | 1 |
| Bagante, F | 1 |
| Gamblin, TC | 1 |
| Pawlik, TM | 1 |
| Brandi, G | 1 |
| De Lorenzo, S | 1 |
| Palloni, A | 1 |
| Biasco, G | 1 |
| Altaii, H | 1 |
| Al-Kindi, SG | 1 |
| Oliveira, GH | 1 |
| Yaqoob, Z | 1 |
| Romero-Marrero, C | 1 |
| Puetkasichonpasutha, J | 1 |
| Yongvanit, P | 1 |
| Techasen, A | 1 |
| Puapairoj, A | 1 |
| Sripa, B | 1 |
| Tassaneeyakul, W | 1 |
| Khuntikeo, N | 1 |
| Wongkham, S | 1 |
2 reviews available for aspirin and Bile Duct Cancer
| Article | Year |
|---|---|
A potential role for aspirin in the prevention and treatment of cholangiocarcinoma.
Topics: Animals; Aspirin; Bile Duct Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Humans; Incidence | 2021 |
Effects of aspirin and non-steroidal anti-inflammatory drugs on the risk of cholangiocarcinoma: a meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bile Duct Neoplasms; Cholangiocarcinoma; Humans; R | 2019 |
1 trial available for aspirin and Bile Duct Cancer
| Article | Year |
|---|---|
Acetylsalicylic acid for metal stent in malignant distal common bile duct obstruction: A randomized controlled trial.
Topics: Aspirin; Bile Duct Neoplasms; Cholangiopancreatography, Endoscopic Retrograde; Cholestasis; Humans; | 2022 |
18 other studies available for aspirin and Bile Duct Cancer
| Article | Year |
|---|---|
Aspirin, Statins, Non-aspirin NSAIDs, Metformin, and the Risk of Biliary Cancer: A Swedish Population-Based Cohort Study.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bile Duct Neoplasms; Bile Ducts, Intra | 2022 |
Does aspirin use influence hepatocellular carcinoma and cholangiocarcinoma prognosis?
Topics: Aspirin; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Hepatocellular; Cholangiocarcinom | 2022 |
Association Between Aspirin and Cholangiocarcinoma in a Large Asian Cohort.
Topics: Aged; Aspirin; Bile Duct Neoplasms; Case-Control Studies; Cholangiocarcinoma; Female; Humans; Incide | 2020 |
Aspirin inhibits cholangiocarcinoma cell proliferation via cell cycle arrest in vitro and in vivo.
Topics: Animals; Apoptosis; Aspirin; Bile Duct Neoplasms; Cell Line, Tumor; Cell Proliferation; Cholangiocar | 2021 |
Postdiagnosis Aspirin Use Associated With Decreased Biliary Tract Cancer-Specific Mortality in a Large Nationwide Cohort.
Topics: Aged; Aged, 80 and over; Ampulla of Vater; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bile Du | 2021 |
Association Between Proton Pump Inhibitor Use and Biliary Tract Cancer Risk: A Swedish Population-Based Cohort Study.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bile Duct Neoplasms; Bile | 2021 |
Aspirin use and the risk of cholangiocarcinoma.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cho | 2019 |
Reply to: 'Effects of aspirin and non-steroidal anti-inflammatory drugs on the risk of cholangiocarcinoma: a meta-analysis'.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cho | 2019 |
Reply to: Effects of aspirin and non-steroidal anti-inflammatory drugs on the risk of cholangiocarcinoma: a meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cho | 2019 |
Effects of aspirin and non-steroidal anti-inflammatory drugs on the risk of cholangiocarcinoma: a meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cho | 2019 |
Aspirin may prevent cholangiocarcinoma: a case-control study from the United kingdom.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bile Duct Neoplasm | 2014 |
Successful multidisciplinary treatment of hilar cholangiocarcinoma in a patient with complicated new-onset coronary artery disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Bile Duct Neoplasms; Bile Ducts, Intr | 2014 |
Combination of Praziquantel and Aspirin Minimizes Liver Pathology of Hamster Opisthorchis viverrini Infection Associated Cholangiocarcinoma.
Topics: Animals; Anthelmintics; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bile Duct Neoplasms; Bile | 2016 |
Aspirin use and the risk of cholangiocarcinoma.
Topics: Aged; Aspirin; Bile Duct Neoplasms; Case-Control Studies; Cholangiocarcinoma; Cohort Studies; Cycloo | 2016 |
Cholangiocarcinoma risk factors and the potential role of aspirin.
Topics: Aspirin; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Humans; Risk Factors | 2016 |
Aspirin for cholangiocarcinoma prevention: New targets to shift the dogma from ascertained risk to possible prevention.
Topics: Aspirin; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cardiovascular Diseases; Cholangiocarcinoma; | 2017 |
Aspirin use and risk of cholangiocarcinoma: External validation with big data.
Topics: Aspirin; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Humans | 2017 |
Downregulation of reversion-inducing-cysteine-rich protein with Kazal motifs (RECK) is associated with enhanced expression of matrix metalloproteinases and cholangiocarcinoma metastases.
Topics: Animals; Aspirin; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cholangiocarcinom | 2011 |